MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.010
-0.040
-1.95%
Closed 16:00 04/03 EDT
OPEN
2.050
PREV CLOSE
2.050
HIGH
2.170
LOW
1.984
VOLUME
56.88K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
1.010
MARKET CAP
58.95M
P/E (TTM)
-1.2638
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRVS stock price target is 9.20 with a high estimate of 15.00 and a low estimate of 6.00.

EPS

CRVS News

More
  • Corvus Pharma files to offer up to $50M in stock
  • seekingalpha · 03/21 03:32
  • Wedbush Maintains Outperform on Corvus Pharmaceuticals, Lowers Price Target to $8
  • Benzinga · 03/13 12:47
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • Edited Transcript of CRVS earnings conference call or presentation 5-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/10 18:24

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.